Strategic question
Which priority markets and venture partners should anchor our future women’s health innovation roadmap, starting with telemedicine?
How Galen Growth helped
From market signal to decision-ready evidence
Powered by HealthTech Alpha, we evaluated ecosystem maturity across five priority markets, assessed patient cohorts, therapeutic mix and bio-pharma partnership activity, and ran structured scouting with expert interviews to validate business models.
Outcomes
Surfaced where women’s health innovation was most defensible to scale and where telemedicine could be adopted first, clarifying market-level white space.
Decision enabled: Enabled the franchise to sequence market entry and focus partnership investment on a prioritised shortlist of ventures.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Tracking Competitor Moves to Support Global Franchise Strategy
How should we track competitor activity across obesity, diabetes and cardiovascular disease to support global strategic decisions?
Benchmarking Global Competitor Partnerships to Prioritise Digital Health Strategy
Where are competitors investing and partnering in Digital Health, and what should that mean for our own portfolio strategy?
Informing Franchise-Level Resource Allocation Across APAC
Which APAC markets should we prioritise for Digital Health investment, and where is our franchise readiness strongest?